Wellington Management Group LLP Buys 15,147 Shares of Urogen Pharma $URGN

Wellington Management Group LLP raised its stake in shares of Urogen Pharma (NASDAQ:URGN) by 15.1% in the 2nd quarter, Holdings Channel.com reports. The institutional investor owned 115,362 shares of the company’s stock after purchasing an additional 15,147 shares during the quarter. Wellington Management Group LLP’s holdings in Urogen Pharma were worth $4,245,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently modified their holdings of the company. Paradigm Biocapital Advisors LP bought a new stake in shares of Urogen Pharma in the 3rd quarter valued at about $84,111,000. BlackRock Inc. bought a new position in Urogen Pharma during the 2nd quarter worth approximately $117,814,000. Jefferies Financial Group Inc. acquired a new position in Urogen Pharma during the second quarter valued at approximately $80,947,000. Soleus Capital Management L.P. acquired a new position in Urogen Pharma during the second quarter valued at approximately $29,934,000. Finally, Healthcare of Ontario Pension Plan Trust Fund bought a new stake in Urogen Pharma in the fourth quarter valued at approximately $26,350,000. 91.29% of the stock is owned by institutional investors.

Insider Transactions at Urogen Pharma

In other news, insider Mark Schoenberg sold 60,677 shares of the business’s stock in a transaction dated Thursday, August 20th. The stock was sold at an average price of $47.05, for a total value of $2,854,852.85. Following the sale, the insider directly owned 59,086 shares in the company, valued at $2,779,996.30. The trade was a 50.66% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, General Counsel Jason Smith sold 1,519 shares of the company’s stock in a transaction dated Tuesday, September 8th. The stock was sold at an average price of $42.54, for a total value of $64,618.26. Following the transaction, the general counsel directly owned 53,141 shares of the company’s stock, valued at $2,260,618.14. This represents a 2.78% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 83,067 shares of company stock valued at $3,706,954. Corporate insiders own 4.80% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on the stock. Guggenheim increased their target price on shares of Urogen Pharma from $42.00 to $58.00 and gave the stock a “buy” rating in a report on Thursday, August 6th. UBS Group reaffirmed a “buy” rating on shares of Urogen Pharma in a research note on Thursday, July 9th. Oppenheimer lifted their target price on Urogen Pharma from $40.00 to $50.00 and gave the stock an “outperform” rating in a report on Thursday, July 16th. The Goldman Sachs Group reissued a “neutral” rating and issued a $44.00 target price on shares of Urogen Pharma in a research note on Wednesday, July 15th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Urogen Pharma in a report on Friday, July 17th. Eight research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Urogen Pharma presently has an average rating of “Moderate Buy” and an average target price of $50.38.

Urogen Pharma Stock Up 2.7%

Urogen Pharma stock opened at $45.00 on Thursday. The stock has a market capitalization of $2.20 billion, a PE ratio of -22.73 and a beta of 1.57. Urogen Pharma has a twelve month low of $15.86 and a twelve month high of $50.81. The company has a 50 day moving average of $43.16 and a 200-day moving average of $31.31.

Urogen Pharma (NASDAQ:URGN) last issued its quarterly earnings data on Wednesday, August 5th. The company reported ($0.28) EPS for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.02). The company had revenue of $72.46 million for the quarter, compared to analyst estimates of $63.55 million. Equities analysts anticipate that Urogen Pharma will post -0.2 EPS for the current fiscal year.

Urogen Pharma Profile

UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra’anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.

The company’s lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.